Insider · CIK 0001270734
Deepika Pakianathan
director
Files at TBPH (Theravance Biopharma, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | TBPH Theravance Biopharma, Inc. | DDisposition to issuer Ordinary Shares | -58,065 | - | - | 6,009 | 18 d ago |
| Sep 23, 2026 | TBPH Theravance Biopharma, Inc. | DDisposition to issuer Ordinary Shares | -6,009 | - | - | 0 | 18 d ago |
| Sep 23, 2026 | TBPH Theravance Biopharma, Inc. | DDisposition to issuer Share Option (Right to Buy)derivative | -17,000 | - | - | 0 | 18 d ago |
| Sep 23, 2026 | TBPH Theravance Biopharma, Inc. | DDisposition to issuer Share Option (Right to Buy)derivative | -6,000 | - | - | 0 | 18 d ago |
| Sep 23, 2026 | TBPH Theravance Biopharma, Inc. | DDisposition to issuer Share Option (Right to Buy)derivative | -28,000 | - | - | 0 | 18 d ago |
| Sep 23, 2026 | TBPH Theravance Biopharma, Inc. | DDisposition to issuer Share Option (Right to Buy)derivative | -22,044 | - | - | 0 | 18 d ago |
| Sep 23, 2026 | TBPH Theravance Biopharma, Inc. | DDisposition to issuer Share Option (Right to Buy)derivative | -23,576 | - | - | 0 | 18 d ago |
| Sep 23, 2026 | TBPH Theravance Biopharma, Inc. | DDisposition to issuer Share Option (Right to Buy)derivative | -24,258 | - | - | 0 | 18 d ago |
| Sep 23, 2026 | TBPH Theravance Biopharma, Inc. | DDisposition to issuer Share Option (Right to Buy)derivative | -13,398 | - | - | 0 | 18 d ago |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.